TickerFacts.

Omeros Corp (OMER): Long-Term Debt

Annual figures by period end, from SEC filings.

$87.90M
As of 2025-12-31
-34.7%
3-year compound annual growth
-17.9%
5-year compound annual growth
$315.29M2016-12-31: $80.52M2017-12-31: $83.83M2020-12-31: $236.29M2021-12-31: $313.46M2022-12-31: $315.29M2023-12-31: $213.16M2024-12-31: $164.90M2025-12-31: $87.90M$87.90M
2016-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$87.90M-46.7%2026-03-31, Balance as of period end
2024-12-31$164.90M-22.6%2026-03-31, Balance as of period end
2023-12-31$213.16M-32.4%2024-04-01, Balance as of period end
2022-12-31$315.29M+0.6%2024-04-01, Balance as of period end
2021-12-31$313.46M+32.7%2023-03-13, Balance as of period end
2020-12-31$236.29Mn/a2022-03-01, Balance as of period end
No annual figure between 2017-12-31 and 2020-12-31.
2017-12-31$83.83M+4.1%2018-03-01, Balance as of period end
2016-12-31$80.52Mn/a2017-03-16, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Omeros Corp (OMER)2025-12-31$87.90M-46.7%
ARS Pharmaceuticals, Inc. (SPRY)2025-12-31$96.37Mn/a
BioAge Labs, Inc. (BIOA)2024-12-31$8.50Mn/a
Zevra Therapeutics, Inc. (ZVRA)2025-12-31$61.93M+4.1%
Akebia Therapeutics, Inc. (AKBA)2025-12-31$48.25M+24.7%
Altimmune, Inc. (ALT)2025-12-31$34.29Mn/a
Tonix Pharmaceuticals Holding Corp. (TNXP)2024-12-31$8.65M-21.4%
Xeris Biopharma Holdings, Inc. (XERS)2025-12-31$220.34M-5.1%
Perspective Therapeutics, Inc. (CATX)2025-12-31$1.62M-3.1%

Compare OMER, SPRY, BIOA, ZVRA side by side · Screen every company in Pharmaceutical Preparations ↗